RPg Family Wealth Advisory LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RPg Family Wealth Advisory LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,826 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. Regeneron Pharmaceuticals makes up about 2.0% of RPg Family Wealth Advisory LLC’s investment portfolio, making the stock its 20th largest holding. RPg Family Wealth Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $6,123,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC increased its holdings in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $28,000. Finally, Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $1,146.75 on Wednesday. The firm has a market capitalization of $126.36 billion, a PE ratio of 33.88, a P/E/G ratio of 3.97 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $1,128.09 and a 200 day moving average price of $1,028.93. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same period last year, the firm posted $8.79 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on REGN. Truist Financial reissued a “buy” rating and set a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,282.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Piper Sandler raised their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,111.30.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.